First Gaucher type 3 neurological drug approved
-
By
-
Teraya Smith
-
November 18, 2026
-
2 min
By
Teraya Smith
November 18, 2026
Expectations of environmental instability declined alongside delusional symptoms during 6 months following an acute psychotic episode.
August 25, 2026
The antisense oligonucleotide reduces production of the abnormal protein that accumulates in supportive cells in the brain.
September 4, 2026